Date: 2011-02-22
Type of
information: Results
phase: 2b
Announcement: results
Company: Medivir (Sweden) Tibotec (J&J group - USA)
Product: simeprevir (TMC435)
Action
mechanism:
- direct-acting antiviral agent/protease inhibitor/RNA polymerase (NS5B) inhibitor/RNA polymerase (NS5A) inhibitor. Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir.
Disease: hepatitis C virus (HCV) genotype-1
Therapeutic
area: Infectious diseases
Country:
Trial
details:
- In the PILLAR study, 75mg or 150mg TMC435 was given for either 12 or 24 weeks in combination with 24 weeks of ribavirin and pegIFNalpha-2A, the current standard of care (SoC). Patients in the TMC435 arms stopped all treatment at week 24 if certain predefined response-guided criteria were met. In the TMC435 treatment groups 83% of patients were able to stop all therapy at week 24. Patients who did not meet the above response-guided criteria continued with SoC until week 48 as did the placebo group. A protocol-defined interim analysis was performed when all patients completed their Week 48 visit or discontinued earlier. Final SVR4 and SVR24 data were available for 98% (303/309; n/N) and 93% (288/309; n/N) of TMC435 treated patients, respectively. SVR24 is determined 24 weeks after the planned end of treatment (EoT) and was therefore not yet available for the patients in the placebo group and for some of those in the TMC435 group who received 48 weeks of treatment. SVR4, which is determined 4 weeks after the planned EoT, was available for 77% (59/77; n/M) of the patients in the placebo group
Latest
news:
- Medivir has announced further positive results from the phase 2b PILLAR (C205) study of TMC435 in treatment-naïve patients with hepatitis C virus (HCV) genotype-1. TMC435 was safe and well tolerated with no clinically relevant differences in adverse events between treatment groups and standard of care (SoC). In the TMC435 treatment groups 83% of patients were able to stop all therapy at week 24. Potent and consistent antiviral efficacy was demonstrated with SVR24 rates of up to 84%. The 48-week interim results from the 5-arm phase 2b response guided PILLAR study in 386 treatment-naïve patients showed further consistent high antiviral activity, and the good safety and tolerability previously demonstrated was confirmed. Potent and sustained antiviral efficacy was demonstrated in the SVR4 and SVR24 rates with no major differences between TMC435 doses or length of triple therapy. At week 4 after cessation of treatment 87.2%, 86.5%, 84.9% and 88.5% of patients taking TMC435 and Peg-IFN/RBV (SoC) achieved undetectable HCV RNA levels. At week 24 after cessation of treatment 83.6%, 76.1%, 83.1% and 84.4% of patients taking TMC435 and Peg-IFN/RBV (SoC) achieved undetectable HCV RNA levels, i.e. SVR24. At week 4 after cessation of treatment 71.2% in the placebo SoC group had achieved undetectable HCV RNA levels.
The results are derived from an intent-to-treat (ITT) analysis of the patient population who took at least one dose of the study medication and who reached the criteria for stopping all treatment at 24 weeks (83%).
Sustained Virological Response 24 Weeks after Planned End of Treatment (EoT);
TMC435 TMC435 TMC435 TMC435 Placebo
12PR24 24PR24 12PR24 24PR24
75mg q.d. 75mg q.d. 150mg q.d. 150 mg q.d.
% (n/N) N=78 N=75 N=77 N=79 N=77
SVR4 87.2 (68/78) 86.5 (64/74) 84.9 (62/73) 88.5 (69/78) 71.2 (42/59)
SVR24 83.6 (61/73) 76.1 (51/67) 83.1 (59/71) 84.4 (65/77) N/A
* < 25 log10 IU/mL undetectable
q.d.: once daily, PR: pegIFNalpha-2A and ribavirin,
SVR4 and SVR24: patients with undetectable HCV RNA 4 and 24 weeks after planned EoT, respectively.
N/A: Patients in the control arm continue SoC until Week 48 and SVR24 data was not available
TMC435 was generally safe and well tolerated and overall incidence of adverse events (AEs) was similar across treatment groups. AEs leading to discontinuation of TMC435 or placebo treatment were reported in 7.8% of the placebo subjects and in 7.1% of the TMC435 treated subjects. In the safety analyses, special attention was given to the following AEs of interest: hepatobiliary AEs, pruritus, rash, anemia, and cardiac events. For each category of AEs of interest; the incidence was similar between TMC435 and placebo.
In laboratory parameters, there were no clinically relevant differences between any TMC435 groups and placebo except for mild on treatment reversible bilirubin elevations (total, direct and indirect) in the 150 mg TMC435 arm, which were normalized after TMC435 dosing was completed. There were no meaningful differences between treatment groups for any of the other laboratory parameters. Significant and rapid decreases in transaminases (ALT and AST) were observed in all TMC435 treatment groups.
Is
general: Yes
